ACELYRIN reports progress in thyroid eye disease treatment

Published 2025-01-06, 04:12 p/m
SLRN
-

ACELYRIN, Inc. (SLRN), a biopharmaceutical company with a market capitalization of $383 million, announced today additional Phase 2 data for its investigational treatment, lonigutamab, for thyroid eye disease (TED) and details of the Phase 3 LONGITUDE program design. According to InvestingPro data, the stock has shown strong momentum with a 24% gain over the past week.

The new data showed lonigutamab's clinically meaningful improvements in TED symptoms, including eye protrusion, inflammation, double vision, and quality of life, without reported cases of hearing impairment, high blood sugar, or menstrual disorders to date.

The Phase 3 LONGITUDE program will consist of two global double-masked, placebo-controlled trials involving approximately 350 patients. The trials will assess the safety and efficacy of a 100mg loading dose of lonigutamab followed by a 50mg dose every two weeks. InvestingPro analysis shows the company maintains a strong liquidity position with a current ratio of 7.15, though it's currently experiencing significant cash burn. The primary endpoint is the proptosis response rate at 24 weeks. All participants will receive the drug from 24 to 52 weeks, potentially allowing long-term treatment benefits.

ACELYRIN has aligned with the U.S. Food and Drug Administration on the Phase 3 trial designs after an end-of-Phase 2 meeting. The company plans to initiate the LONGITUDE program in the first quarter of 2025 and expects to report top-line data in the second half of 2026.

These forward-looking statements are subject to risks and uncertainties that could affect the company's actual results. ACELYRIN's future reports to the Securities and Exchange Commission will provide further details on risk factors and other conditions that may impact the company's operations and projections.

With analyst price targets ranging from $5 to $20, investors seeking deeper insights can access comprehensive analysis and 8 additional ProTips through InvestingPro's detailed research reports, which provide essential metrics and expert analysis for over 1,400 US stocks.

In other recent news, Acelyrin Inc. has made significant strides in its clinical trials. The biopharmaceutical firm has advanced its drug lonigutamab into Phase 3 trials for the treatment of Thyroid Eye Disease (TED), following promising Phase 2 data. The Phase 3 program, named LONGITUDE, is set to commence in the first quarter of 2025, with topline data expected in the latter half of 2026.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2025 - Fusion Media Limited. All Rights Reserved.